Conference Correspondent

Conference Correspondent | January 16, 2020
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Conference Correspondent | January 16, 2020
Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features.
Conference Correspondent | January 16, 2020
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Conference Correspondent | January 16, 2020
A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs.
Conference Correspondent | January 16, 2020
The results of this phase 3 study demonstrate a progression-free survival advantage for patients treated with acalabrutinib given alone or in combination with obinutuzumab versus those treated with obinutuzumab plus chlorambucil.
Conference Correspondent | December 20, 2019
Read about 3 key adverse events often encountered by patients with multiple myeloma, along with simple steps nurses can take to prevent them or handle them appropriately if encountered.
Conference Correspondent | December 20, 2019
For multiple myeloma, triplet therapy is a new standard of care that replaces doublet therapy for most patients. Adding a third drug may seem simple enough, but practitioners need to be aware of unique benefits and risks.
Conference Correspondent | December 20, 2019
When managing patients with newly diagnosed active multiple myeloma, providing the most appropriate first-line therapy – also known as “upfront” treatment – is essential to achieving the best possible outcome.
Conference Correspondent | December 20, 2019
Read about how investigators have turned to new diagnostics that have led to new response categories based on minimal residual disease (MRD).
Conference Correspondent | December 20, 2019
Chimeric antigen receptor (CAR) T-cell therapy may soon be a treatment option for patients with multiple myeloma, according to leading experts. CAR T-cells, which are immune cells genetically modified to target cancer antigens, are already FDA-approved for the treatment of patients with leukemia and lymphoma, conditions in which CAR T-cell therapy can achieve long-term disease control.
Page 1 of 6
Results 1 - 10 of 53

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code